XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Dec. 30, 2022
Cover [Abstract]  
Amendment Flag true
Entity Central Index Key 0000025743
Document Type 8-K/A
Document Period End Date Dec. 30, 2022
Entity Registrant Name THERAPEUTICSMD, INC.
Entity Incorporation State Country Code NV
Entity File Number 001-00100
Entity Tax Identification Number 87-0233535
Entity Address, Address Line One 951 Yamato Road
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code (561)
Local Phone Number 961-1900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol TXMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Description TherapeuticsMD, Inc., a Nevada corporation (the “Company”), previously filed a Current Report on Form 8-K dated December 30, 2022 (the “Current Report”) with the Securities and Exchange Commission on January 3, 2023 to report the Company completed its previously announced transaction (the “Transaction”) with Mayne Pharma LLC, a Delaware limited liability company (“Mayne Pharma”) and subsidiary of Mayne Pharma Group Limited, an Australian public company (ASX: MYX), pursuant to which the Company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize the Company’s Imvexxy®, Bijuva® and prescription prenatal vitamin products sold under the BocaGreenMD® and vitaMedMD® brands in the United States and its possessions and territories, (ii) assigned to Mayne Pharma the Company’s exclusive license to commercialize Annovera® in the United States and its possessions and territories, and (iii) sold certain other assets to Mayne Pharma in connection therewith. With the completion of the closing of the above transactions, the Company was able to recapitalize and transform into a pharmaceutical royalty company (the “Transformation”).